Unveiling the role of ferroptosis in the progression from NAFLD to NASH: recent advances in mechanistic understanding

Non-alcoholic fatty liver disease (NAFLD) is a prevalent and significant global public health issue. Nonalcoholic steatohepatitis (NASH) represents an advanced stage of NAFLD in terms of pathology. However, the intricate mechanisms underlying the progression from NAFLD to NASH remain elusive. Ferroptosis, characterized by iron-dependent cell death and distinguished from other forms of cell death based on morphological, biochemical, and genetic criteria, has emerged as a potential participant with a pivotal role in driving NAFLD progression. Nevertheless, its precise mechanism remains poorly elucidated. In this review article, we comprehensively summarize the pathogenesis of NAFLD/NASH and ferroptosis while highlighting recent advances in understanding the mechanistic involvement of ferroptosis in NAFLD/NASH.


Introduction
Over the past few decades, NAFLD has emerged as the most prevalent chronic liver disorder and a leading cause of death and morbidity worldwide, garnering significant attention from hepatologists and metabolism experts.NAFLD can progress to a more severe form called NASH, which is associated with advanced liver diseases like cirrhosis and hepatocellular carcinoma, ultimately resulting in mortality (1).Therefore, preventing the progression from NAFLD to NASH is crucial for reducing mortality rates.Although systematic studies have established a close bidirectional association between NAFLD and metabolic disorders such as obesity, insulin resistance, and abnormal iron homeostasis (2)(3)(4), the precise mechanisms underlying this progression remain to be explored.
Recently, accumulating evidence strongly suggests that ferroptosis plays a significant role in the pathogenesis of NAFLD.For instance, the liver serves as a crucial iron reservoir and is involved in various aspects of iron metabolism, including absorption, utilization, storage, and secretion (10).Studies have indicated that NAFLD patients exhibit elevated serum ferritin levels and serum ferritin levels are associated with histologic severity and advanced fibrosis in NAFLD patients (11,12).Consistent with this, excessive iron accumulation can contribute to hepatocyte fibrosis (13,14).Additionally, ferroptosis has been shown to induce oxidative stress, establishing a link between ferroptosis and NAFLD (15).Therefore, an updated review elucidating the role and mechanism of ferroptosis in the progression from NAFLD to NASH is imperative for enhancing our understanding of this disease and controlling mortality rates.In this review article, we provide a concise summary of the pathogenesis underlying NAFLD/NASH and discuss recent advancements regarding the interplay between ferroptosis and NAFLD/NASH.

Pathogenesis of NAFLD
As a prominent cause of chronic liver disease globally, NAFLD is not solely a metabolic disorder but encompasses a spectrum of conditions ranging from non-progressive patterns (nonalcoholic fatty liver, NAFL) to progressive patterns (NASH), ultimately leading to cirrhosis and liver carcinoma.Pathologically, it is characterized by the presence of steatosis in more than 5% hepatocytes without excessive alcohol consumption or other chronic liver diseases (16).Although the precise mechanism underlying the progression from NAFL to NASH remains elusive, numerous studies have demonstrated initiating factors including an imbalance of fat metabolism, insulin resistance, cellular stress, immune infiltration and inflammatory reactions (2,(17)(18)(19)(20).

Fat metabolism in NAFLD
Overnutrition, characterized by excessive consumption of any food, can disrupt liver energy metabolism balance.In this context, the intake of carbohydrates (mono-, di-and polysaccharides) and fat exceeds the body's expenditure, resulting in a net accumulation of energy as triglycerides in the liver and white adipose tissues (WAT), which can account for the NAFLD in obese individuals (21).Additionally, apart from lipolysis of absorbed fat in the intestine, augmented hepatic de novo lipogenesis (DNL) fueled by excess glucose also leads to an increased flux of free fatty acids (FFAs) into the liver (Figure 1).Moreover, expansion of adipose tissue reservoirs in both the liver and WAT creates a susceptible environment where macrophages infiltrate and become activated due to various stimuli such as endotoxins, adipokines, lipids, and lipid metabolites (22).Subsequently, this proinflammatory state promotes insulin resistance-a defect associated with metabolic syndrome and type 2 diabetes-thus accelerating NAFLD progression through sustained delivery of fatty acids to the liver (23).Interestinglyenough, dyslipidemia resulting from irregular dietary habits can contribute to insulin resistance; conversely, insulin dysfunction caused by other factors can also lead to abnormal adipose metabolism (24,25).Although NAFLD prevalence among obese individuals is reported up to 75.27%; another study has demonstrated that within the NAFLD population approximately 40.8% were non-obese individuals who eventually accounted for 19.2% lean subjects (26,27).The plausible mechanism underlying this phenomenon involves impaired storage capacity within subcutaneous adipose tissue forcing fat migration towards visceral adipose tissues and ultimately leading to insulin resistance and NAFLD (28).

Insulin resistance in NAFLD
Insulin resistance is a pivotal factor underlying the progression from NAFL to NASH.As the master regulator of hepatic glucose and adipose metabolism, insulin secreted to the portal vein exhibits two-to threefold higher concentrations than peripheral plasma (29).It exerts multiple crucial biological effects that maintain homeostasis and prevent dysregulation (30).Following a meal, increased insulin levels directly activate insulin receptor tyrosine kinase, leading to reduced hepatic glucose concentration through enhanced glucose uptake and consumption in tissue cells (31).This process accelerates hepatic glycogen synthesis while inhibiting gluconeogenesis, thereby decreasing DNL in the liver (31).In addition to this direct mechanism of transcriptional regulation in hepatic gluconeogenesis, there exists a faster indirect mechanism involving the reduction of peripheral white adipose tissue (WAT) lipolysis through IRTK/AKT2 pathway (29).This change acutely influences hepatic acetyl-CoA content and pyruvate carboxylase activity via substrate push and allosteric mechanisms (23).Furthermore, decreased peripheral WAT lipolysis also impacts the flux of fatty acids into the liver as substrates for triglyceride synthesis (32).

Oxidative stress and cell death in NAFLD
The imbalance of adipose metabolism also creates a lipotoxic microenvironment, wherein the increased oxidation of free fatty acids generates an excessive production of reactive oxygen species (ROS), which serves as a key driver of cellular stress, including oxidative stress and endoplasmic reticulum (ER) stress (18).Subsequently, ROS-induced oxidative stress can activate a series of inflammatory reactions through the nuclear factor-kB (NF-kB) pathway and mitogen-activated protein kinases (MAPK) pathway (33,34).Moreover, the elevated ROS production not only leads to ER stress but is reciprocally influenced by it, thereby establishing a detrimental cycle (35).Additionally, ROS can stimulate hepatic stellate cells (HSCs) to produce collagen type I via NADPH oxidase (NOX), which is considered a crucial biomarker for fibrogenesis (36).These disruptions in internal environment homeostasis trigger complex and interdependent inflammatory and immune signaling pathways that ultimately result in hepatocyte injury characterized by hepatocyte ballooning and cell death -key histological features of NASH (37).Although hepatocyte ballooning represents specialized cellular degeneration rather than cell death per se, it can still enhance pericellular inflammation and fibrotic signaling (38).Mechanisms underlying hepatocyte death primarily involve apoptosis, necroptosis, and pyroptosis.Apoptosis is programmed cell death mediated by various factors such as apoptosis signalingregulated kinase 1 (ASK-1), caspase, and FADD-like apoptosis regulator (39)(40)(41).In contrast to apoptotic mechanisms that do not influence pericellular inflammation or damage significantly, both necroptosis and pyroptosis are pathological forms of cell death associated with cell swelling and membrane rupture leading to the release of inflammatory signals (20).Respectively, necroptosis is regulated by a cascade phosphorylation of RIPK1/RIPK3, while pyroptosis relies on gasdermin family proteins that create pores in the plasma membrane (42)(43)(44).These intricate interactions between cell injury, cell death, and proinflammation establish a fibrogenesis milieu where paracrine inflammatory signals from various cells (e.g., hepatocytes, hepatic stellate cells, liver sinusoidal endothelial cells, macrophages, and neutrophils) drive fibrosis by CCR2, CCL5/ CCR5, CXCL10 and CCL20 (45)(46)(47)(48).
3.1 Xc _ /GSH/GPX4 axis GPX (glutathione peroxidase) is a protein superfamily that consists of eight isoforms in mammals, with only five of them (GPX 1-4 and 6) being seleno-proteins, while GPX 5,7,8 are nonseleno proteins (54).Among all the GPXs, GPX4 is the sole enzyme responsible for directly catalyzing the reduction of lipid peroxides (54).Depletion of GPX4 in mice leads to embryonic lethality, indicating its crucial role in physiology (55).Animal trials have demonstrated that knockout mice lacking GPX4 die shortly after birth due to extensive hepatocyte degeneration; however, lipophilic antioxidant vitamin E can protect hepatocytes against lipid Glucose and lipid metabolism in the liver.The liver plays a crucial role in numerous physiological processes, particularly in metabolism.Subsequent to a meal, the heightened glucose levels trigger insulin secretion, thereby facilitating metabolic processes such as glycogenesis, glycolysis, and fatty acid synthesis.Moreover, excessive glucose can stimulate de novo lipogenesis within the liver.Conversely, fatty acids can also be converted into glucose through the gluconeogenesis pathway.Additionally, the liver is responsible for assembling very low-density lipoprotein (VLDL) and transporting endogenous triglycerides to peripheral organs.peroxidation (56).Additionally, various diseases such as clear-cell carcinomas, gastric cancer, and diabetic nephropathy have been associated with GPX4 (57-59).Ferroptosis is associated with irondependent ROS, but the GPX4 enzyme can mitigate lipid peroxidation.Yang et al. have demonstrated that depletion of glutathione (GSH) can inactivate the GPX4 enzyme, leading to ferroptosis initiation (60).System Xc-is widely distributed in the phospholipid bilayer and serves as a crucial component of the cellular antioxidant system.It consists of a heterodimeric protein comprising a light chain SLC7A11 and a heavy chain SLC3A2 (61).System Xc-primarily imports cystine and exports glutamate in a 1:1 ratio, with cysteine being an essential precursor for GSH synthesis (61).GPX4 utilizes GSH as a cofactor to convert glutathione into oxidized glutathione (GSSG) while reducing cytotoxic lipid peroxides to non-toxic lipid alcohols (62).Gao et al. discovered that both glutamine or cystine starvation could induce ROS accumulation, resulting in lipid peroxidation and ferroptosis (63).Consequently, depletion of GSH can deactivate GPX4, thereby initiating ferroptosis through inhibition of system xc-or GPX4 compounds, leading to toxic lipid ROS accumulation (64,65).In addition, using the ferroptosis inducer erastin or the GPX4 inhibitor (1S,3R)-RSL3 ultimately leads to lipid peroxidation as well (66,67).More recently identified transcript variants of GPX4 include cytosolic (cGPX4), mitochondrial (mGPX4), and nuclear (nGPX4) (68).Among these isoforms, cGPX has been shown to inhibit ferroptosis and protect against NAFLD in mice (69).However, a newly discovered isoform named iGPX aggravates liver damage and contributes to ferroptosis under NAFLD conditions (69).Nevertheless, in some cell types or cell lines, the inhibition of GPX4 cannot induce ferroptosis, suggesting the presence of alternative mechanisms distinct from GSH-dependent pathways (70).phosphorylation via the electron transport chain.Dihydrooriotic dehydrogenase (DHODH), a CoQ10-reducing flavoprotein to FSP1, localizes to the mitochondria and operates parallelly with mitochondrial GPX4 to inhibit ferroptosis by reducing CoQ to CoQH2, thereby preventing lipid peroxidation (73).Additionally, the FSP1-ESCRT-III-dependent membrane repair pathway is implicated in ferroptosis (74).Excessive lipid oxidation ultimately leads to membrane rupture, and studies have shown that endosomal sorting complexes required for transport (ESCRT) mediate cell membrane remodeling and fission reactions (75).In mammalian cells, the ESCRT-III complex comprises 12 subunits known as charged multivesicular body proteins (CHMPs) (76).Among these proteins, CHMP5 and CHMP6 are crucial subunits of ESCRT-III associated with resistance against ferroptosis through membrane budding and fission; knockdown of CHMP5 or CHMP6 increases susceptibility to erastin-and RSL3-induced ferroptosis (77).Zeng et al. also observed that knockdown of FSP1 suppressed RSL3-induced expression of charged CHMP5 and CHMP6 at the plasma membrane while overexpression of CHMP5 rescued cell death induced by RSL3, erastin, and sorafenib both in wild-type cells as well as those silenced for FSP1 (76).

GCH1/BH4 axis in ferroptosis
Tetrahydrobiopterin (BH4) serves as a coenzyme for aromatic amino acid hydroxylases, including 5-hydroxytryptamine, dopamine, noradrenaline, adrenaline, and melatonin.Additionally, BH4 acts as a crucial cofactor for nitric oxide synthase.Exogenous administration of dopamine or melatonin has been demonstrated to suppress erastin-or hemin-induced ferroptosis in diverse cell types (78, 79).Moreover, BH4 plays a pivotal role in antioxidant defense and the removal of nitrogen oxides (80).Elevated levels of BH4 inhibit ferroptosis and confer resistance against erastin-induced cell death (81,82).Mariluz observed that cells depleted of BH4 exhibited heightened lipid peroxidation upon GPX4 inhibition, but this effect was reversed by supplementation with BH2 (83).This finding further supports the notion that BH4 can impede ferroptosis by preventing lipid peroxidation.GTP cyclohydrolase-1 (GCH1), the rate-limiting enzyme in BH4 synthesis, selectively protects certain PUFA-PLs from degradation to alleviate oxidation and enhance resistance against ferroptosis (82).In summary, the GCH1/BH4 axis functions as a master regulator of ferroptotic resistance through its ability to block lipid peroxidation.

Lipid peroxidation in ferroptosis
Polyunsaturated fatty acids (PUFAs) containing bis-allylic hydrogen atoms are susceptible to lipid peroxidation, and emerging evidence suggests that PUFAs play a crucial role in the execution of ferroptosis (84).The dysregulation of lipid metabolism, characterized by increased PUFAs and decreased monounsaturated fatty acids (MUFAs), contributes to the generation of lipid peroxides, which drive ferroptosis through their incorporation into membrane phospholipids (85,86).Kagan et al. demonstrated that hydroperoxy derivatives of polyunsaturated fatty acidphosphatidylethanolamines (PUFA-PLs) can induce ferroptosis even in cells with GPX4 inactivation (87).Among PUFAs, arachidonic acid and adrenic acid are particularly important phospholipids involved in oxidation processes, while acyl-CoA s y n t h e t a s e l o n g -c h a i n f a m i l y m e m b e r ( A C S L ) a n d lysophosphatidylcholine acyltransferase 3 (LPCAT3) serve as key enzymes in lipid metabolism (88).PUFAs can undergo oxidation by ROS or LOX to form LOOHs, which subsequently generate uncontrolled lipid free radicals through Fenton-like reactions.In the presence of iron, lipid peroxides are converted into toxic lipid free radicals (LO-), leading to cellular death (8).ACSL enzymes activate free fatty acids to produce fatty acyl-CoA, which can then be incorporated into glycerophospholipids.It has been demonstrated that ACSL4 exhibits a strong preference for activating PUFAs and its deletion prevents the incorporation of PUFAs into membrane phospholipids where they would undergo oxidation following GPX4 inactivation (88).ACSL4 binds PUFAs to membrane phospholipids, creating conditions conducive for ferroptosis, while ROS directly generate PUFA-PLOOH triggering ferroptosis.In the presence of Fe2+, PUFA-PLOOH can be reduced to PUFA-PLO•, facilitating rapid chain reaction diffusion and subsequent ferroptosis (89).Furthermore, ACSL3 has also been found highly relevant to ferroptosis as it activates MUFAs that reduce plasma membrane lipids' susceptibility to oxidation (90).Magtanong et al. further stated that ACSL3-dependent activation of MUFAs promotes a cell state resistant to ferroptosis (91).

Ferroptosis drives NAFLD to NASH
Cell death is a pivotal histologic hallmark of NASH that contributes to the amplification of inflammatory signaling and fibrogenesis.Among various forms of cell death in NASH, ferroptosis may serve as a potential trigger for initiating inflammation in steatohepatitis (92).In the early stages of NAFLD, the accumulation of lipid droplets creates a lipotoxic environment, leading to redox imbalance (93).Bioinformatics analysis revealed higher expression levels of genes involved in the "ferroptosis" pathway and "glutathione metabolism" pathway, such as ACSL6, ACSL4, GSS, GPX2, and GPX3 in individuals with NASH compared to healthy controls; meanwhile, the expression of iron exporter ferroportin (SLC40A1) was down-regulated (94).Overall, ferroptosis is closely associated with NAFLD/NASH through underlying mechanisms including iron overload, oxidative stress, and overwhelming membrane lipid peroxidation.

The role of iron overload between ferroptosis and NAFLD/NASH
Iron plays a diverse range of crucial roles in physiological metabolism in vivo.In addition to its role as an element bound to proteins for essential cellular functions such as ATP generation, DNA and repair, and oxygen transport, iron is also an indispensable component of the redox system, switching between Fe2 + and Fe3 + (95).Abnormal accumulation of iron within cells and impaired binding capacity of iron-containing proteins can result in increased levels of redox-active iron, which generates oxygen radicals through Fenton chemistry, leading to detrimental effects on DNA, proteins, and lipids (50).Nevertheless, clinical analysis has shown that elevated serum ferritin levels are independently associated with advanced NAFLD (11).This observation implies an augmentation in iron reserves and systemic inflammation within the context of NAFLD.Ferritin heavy chain (FTH) and ferritin light chain (FTL) are crucial ironassociated factors.Recently, Crawford et al. reported that reducing iron intake attenuates NAFLD in a high-calorie-induced mouse model while Deng et al. demonstrated that Caveolin-1 enhances ferritin synthesis and increases iron storage capacity by activating the FTL/FTH pathway, subsequently decreasing ROS levels and alleviating NAFLD progression (96,97).Furthermore, Yu et al. have reported that Fe3 + chelation can reverse iron overload in vivo thereby attenuating the production of lethal ROS while alleviating ER stress and regulating the Nrf2/NF-kB signaling pathway (98).These findings propose a potential therapeutic strategy for NAFLD/ NASH.Emerging evidence suggests that aberrant iron distribution contributes to a novel mechanism underlying NAFLD development; elevated secretion of iron-containing extracellular vesicles leads to hepatocyte iron deficiency which enhances lipogenesis and insulin resistance through HIF2a-ATF4 signaling whereas HSC-mediated iron overload promotes fibrogenesis via excessive ROS production (99).

The role of lipid peroxidation and ROS between ferroptosis and NAFLD/NASH
The pathogenesis of ferroptosis in NAFLD/NASH is closely associated with lipid peroxidation and abnormal accumulation of reactive oxygen species (ROS).For instance, in a methioninecholine deficient (MCD) diet-induced mice model, elevated arachidonic acid metabolism promotes ferroptosis, while the use of ferroptosis inhibitors alleviates inflammation, fibrogenesis, and liver injury (100).This was confirmed by measuring levels of lipid ROS and iron.
ACSL4 is a crucial enzyme that catalyzes CoA to PUFAs such as arachidonic acid, which can promote ferroptosis.Clinical studies have reported increased hepatic ASCL4 levels in NAFLD patients compared to healthy controls (101).Further research has shown that suppressing ACSL4 expression significantly improves NAFLD symptoms in multiple mouse models (101).Consistent with this finding, another study demonstrated that the ferroptosis inhibitor liproxstatin-1 (LPT1) not only reduced the expression of ACSL4 but also decreased hepatic lipids (e.g., triglycerides, cholesterol), lipid metabolites (e.g., 4-hydroxynonenal, malondialdehyde), insulin resistance, mitochondrial ROS content and liver fibrosis (102).Moreover, recent investigations on lung injury revealed that deletion of the ACSL4 gene suppresses ferroptosis and attenuates chemical-induced lung injury and pulmonary fibrosis by reducing PUFA-containing membrane phospholipids and inhibiting lipid peroxide formation (103).
The Xc-/GSH/GPX4 axis represents a central antioxidant pathway in ferroptosis.Studies have demonstrated that treatment with the ferroptosis inducer RSL-3 can decrease hepatic expression of GPX4, leading to more severe symptoms in an MCD-induced NASH mice model (66).Consistent with this, administration of the GPX4 activator sodium selenite and the ferroptosis inhibitor liproxstatin-1 can attenuate NASH severity (66).SLC7A11, a subunit of System Xc-, also plays critical roles in both ferroptosis and NAFLD/NASH pathogenesis.In high-fat diet-induced NASH mice models, hepatocyte ATF4 ablation increases susceptibility to ferroptosis and hepatocarcinogenesis; however, ectopic expression of SLC7A11 reverses these effects (104).Similarly, another study revealed that Arbutin, a natural antioxidant compound, reduces ferroptosis and ameliorates high-fat diet (HFD) induced NAFLD both in vivo and in vitro by regulating methylation of the SLC7A11 gene through inhibition of fat mass and obesity-related protein (FTO) (105).

Other regulatory factors between ferroptosis and NAFLD/NASH
In addition, several studies have also reported additional potential regulatory pathways linking ferroptosis and NAFLD/ NASH.The key regulatory factors include PRDX3, Lgfbp7, and Mfn2.For instance, the accumulation of phospholipid peroxides can lead to hyperoxidation of peroxiredoxin 3 (PRDX3), promoting its translocation from mitochondria to the plasma membrane.This subsequently inhibits cystine uptake and induces ferroptosis (106).Recently, a study in a zebrafish model has elucidated that Lgfbp7 may regulate ferroptosis through Ncoa4-mediated ferritinophagy, with depletion of Lgfbp7 reducing hepatic iron deposition and lipid peroxidation products (107).Furthermore, Mitofusin 2 (Mfn2) could interact with inositol-requiring enzyme 1 alpha (IRE1a) to promote ferroptosis in an arsenic-induced NASH model (108).
Moreover, the pathogenic pathways are also influenced by genetic and microbiome-related factors (109).For example, Zhuge et al. proposed a possible mechanism for impaired function of antifibrotic drugs whereby gut microbiota induces lipid peroxidation and ROS accumulation to promote hepatocyte ferroptosis and activate HSCs by generating excessive chenodeoxycholic acid (110).

The heterogeneity of animal models on NAFLD/NASH
In this review, we have discussed four mouse models simulating the pathological process of human NAFLD/NASH, including the MCD-induced model, HFD-induced NASH model, CDE-induced model, and arsenic-induced NASH model.The first three models represent dietary intervention approaches, while the last one represents toxin exposure.However, not all models successfully replicate the etiology and features of human NASH.For example, the HFD model induces hepatic steatosis, insulin resistance, inflammation and ER stress but lacks fibrosis and NASH development; both the MCD and CDE models can induce NASH-like pathology in mice but do not exhibit insulin resistance (111).Therefore, a combination of multiple strategies such as HFD+fructose and CD+HFD is widely employed to induce insulin resistance, dyslipidemia, ER stress, fibrosis and NASH (111).Additionally, the arsenic exposure model has been reported to cause lipid accumulation, increase TNF levels, and result in liver injury (112).Furthermore, toxins or genetics plus diet-based models are also extensively used in NASH research (111).

The relevance between ferroptosis and NAFLD/NASH in human patients
Ferroptosis is associated with the Xc-/GSH/GPX4 axis, the FSP1/CoQ axis, the GCH1/BH4 axis, lipid peroxidation, and iron overload.Abundant clinical research has demonstrated that these mechanisms are involved in NAFLD/NASH.For example, serum ferritin levels are increased in NAFLD and hyperferritinemia is associated with advanced NASH and fibrosis (11).Consistent with this finding, another study has shown that patients with hyperferritinemia have higher iron stores and more severe liver fibrosis (113).A clinical cohort analysis reported that oral supplementation of whey protein in patients with NASH can increase plasma GSH levels, thereby reducing hepatic macrovesicular steatosis (114).Recently, novel evidence has revealed that hepatic expression of SLC7A11 is upregulated in NASH patients and positively correlates with disease severity (115).Moreover, a pathological analysis conducted on metabolic-associated fatty liver disease (MAFLD) patients demonstrated elevated levels of malondialdehyde (a marker for lipid peroxidation), while total superoxide dismutase (SOD) activity and total antioxidant capacity (TAC) were decreased in liver tissues from MAFLD patients (69).Additionally, mRNA levels of NOX1, NOX4, FTH,and FTL were also found to be higher in livers from MAFLD patients compared to controls (69).These clinical results provide incontrovertible evidence indicating the significant role of ferroptosis in the progression of NAFLD/NASH.

Targeting ferroptosis in NAFLD/NASH
Currently, Rezdiffra has gained approval from the Food and Drug Administration (FDA) for the treatment of NAFLD/NASH (116), marking a significant milestone in the advancement of therapeutics for this condition.In this review, we have presented various mechanisms targeting ferroptosis that can potentially mitigate or prevent the progression of NAFLD to NASH.These targeted approaches are summarized in Table 1.However, it is important to note that these strategies have primarily been investigated in preclinical models, and there is currently no commercially available drug specifically designed to target ferroptosis for the treatment of NAFLD/NASH.

Conclusion
NAFLD/NASH has emerged as a critical public health concern, necessitating further investigation into its underlying mechanisms and treatment strategies.Conversely, the development of an accurate predictive tool for identifying individuals at risk of transitioning from NAFLD to NASH could significantly impact mortality rates.Notably, in a choline-deficient, ethioninesupplemented (CDE) diet model, inhibition of ferroptosis effectively prevents initiation of necrotic cell death and suppresses inflammatory reactions and immune cell infiltration (92).This underscore the importance of targeting ferroptosis as a potent therapeutic strategy to impede disease progression from NAFLD to NASH in the future.Although numerous animal models have provided substantial evidence demonstrating that inhibiting ferroptosis exerts significant effects on NAFLD/NASH, their precise mechanisms remain elusive.Furthermore, clinical research investigating pharmacological therapies aimed at inhibiting ferroptosis for treating NAFLD/NASH is currently lacking.
Herein, we summarize recent advances in understanding the mechanistic involvement of ferroptosis in NAFLD/NASH pathogenesis.This review article provides a novel perspective on the progression from NAFLD to NASH and these underlying mechanisms may have broader implications in other diseases such as idiopathic pulmonary fibrosis (IPF).In conclusion, ferroptosis

FSP1
(ferroptosis suppressor protein 1) can protect against ferroptosis in the absence of GPX4 by utilizing ubiquinone (CoQ10)(70,71).Dai et al. discovered that FSP1 inhibits ferroptotic cell death and reduces CoQ10 levels following treatment with erastin, sorafenib, and RSL3 (72).Bersuker et al. also demonstrated that myristoylated FSP1 functions as an NAD(P) H-dependent oxidoreductase in the plasma membrane to decrease CoQ10 and generate a lipophilic radical trapping antioxidant (RTA), which effectively halts lipid peroxide propagation(70).As it is well known, mitochondria produce ATP through oxidative

FIGURE 2 the
FIGURE 2the mechanism of ferroptosis.Ferroptosis is regulated by Xc _ /GSH/GPX4 axis, FSP1/CoQ10 axis, and PUFA-PLOOH.Membrane system xc-mediates cystine uptake into cell that is followed by GSH synthesis.FSP1 functions as an NADH-dependent CoQ, and CoQ is sufficient to suppress lipid peroxidation.ACSL4 and LPCAT3 are necessary for ferroptosis to produce PUFA-PLOOH.

TABLE 1
Targeting ferroptosis in NAFLD/NASH.Yu and Song 10.3389/fendo.2024.1431652Frontiers in Endocrinology frontiersin.orgplays a crucial role in the pathogenesis of NAFLD/NASH offers novel therapeutic and predictive avenues for patients.